Impact of Perianal Inflammatory Lesions in Crohn's Disease Patients with Anorectal Cancer Authors: Nobuaki Hoshino, Koya Hida, Kazutaka Obama, Yusuke Fujii, Takuya Takami, Tatsuki Noguchi, Kenichi Sugihara, Yoichi Ajioka, Soichiro Ishihara, from the Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by Japanese Society for Cancer of the Colon and Rectum Published: 2026 ABSTRACT Objectives: Perianal inflammatory lesions (PILs), such as anal fistulas and perianal abscesses, are major complications of perianal Crohn's disease (CD). These lesions reflect inflammation status of CD and pose a risk of carcinogenesis. Their presence may be a risk factor for surgical complications and poor prognosis; however, their impact on CD patients with anorectal cancer is not well understood. Methods: This nationwide multicenter observational study included patients with CD who underwent abdominoperineal resection or total pelvic exenteration for anorectal cancer. Patients with distant metastases were excluded. Data collected by the Japanese Society for Cancer of the Colon and Rectum from 43 participating hospitals between January 1983 and December 2020 were analyzed according to the presence or absence of PILs. Postoperative complications, overall survival, and relapse-free survival rates were compared between groups. Results: A total of 173 patients (135 with and 38 without PIL) were included. Postoperative complications were not significantly different between the patients with and without PILs (46.2% vs 45.9%, P=1.000). Five-year overall survival was 73.3% (95% confidence interval (CI) 48.8-87.4%) in patients without PILs, which was significantly higher than the 46.8% (95%CI 36.4-56.6%) in those with PILs (P=0.027). Five-year relapse-free survival was 52.5% (95% CI 30.8-70.3%) in patients without PILs, which was higher than the 40.2% (95%CI 30.6-49.5%) in those with PILs, without statistical significance (P=0.065). Conclusion: In patients with CD and anorectal cancer, the presence of PILs did not increase the incidence of postoperative complications; however, it worsened prognosis. Introduction Crohn's disease (CD) is a chronic inflammatory bowel disease associated with inflammation and ulceration in the digestive tract[1,2]. CD is associated with a wide variety of symptoms, including abdominal pain, diarrhea, bloody stools, fever, anal pain and swelling, and weight loss[3]. The mainstay of treatment for CD is nutritional and drug therapy, but surgery is necessary when complicated by gastrointestinal perforation, intraabdominal abscess/fistula, perianal abscess, anal fistula, or the onset of gastrointestinal cancer[4]. Perianal lesions, including anal fistulas, perianal abscesses, skin tags, perianal fissures, ulcers, and stenosis have been reported to be present in 50% of newly diagnosed CD cases. Among them, perianal inflammatory lesions (PILs), such as anal fistula and perianal abscess, are the most common complications of perianal CD[5]. Their prevalence is estimated to be as high as 40%[6]. They are present on the surface of the body, are easily recognized as CD, and are often associated with pain and pus drainage, leading to decreased quality of life[7]. Treatment strategies for PILs vary, but they generally require long-term drug or surgical treatment and may involve recurrent flare-ups[8,9]. The presence of PILs in CD indicates increased disease aggressiveness and is considered to be a poor prognostic factor[10]. Similarly, in patients with CD complicated by anorectal cancer, the prognosis may also worsen with postponement of chemotherapy because of PILs or decreased quality of life. However, the prevalence of CD in patients with colorectal cancer is as low as 0.6% and no study has examined the influence of PILs in CD patients with anorectal cancer[11]. This study aimed to investigate the short-term and long-term impact of PILs on CD patients with anorectal cancer. Patients and Methods Study design and setting This was a nationwide multicenter observational study. Information on patients who underwent abdominoperineal resection (APR) or total pelvic exenteration (TPE) for anorectal cancer was extracted from the Japanese Society for Cancer of the Colon and Rectum (JSCCR) data on CD patients with gastrointestinal cancer between January 1983 and December 2020 who were treated at any of the 43 participating hospitals. To assess the impact of PILs on postoperative complications and prognosis more accurately, the surgical procedures included in this study were limited to APR and TPE. Patients with no information on PILs, and those with distant metastases were excluded. Anal fistulas and perianal abscesses at cancer diagnosis were defined as PILs. The incidence of postoperative complications, overall survival (OS), and recurrence-free survival (RFS) were compared between patients with and without PILs. OS was defined as the time interval between the dates of surgery and death, and RFS was defined as the time interval between the dates of surgery and recurrence or death, whichever occurred first. This study was approved by the Ethics Committee of Kyoto University (ID: R2348) and this study was conducted in accordance with Declaration of Helsinki. The need for informed consent was waived in view of the anonymity of the data. Statistical analysis Categorical variables are presented as numbers and percentages and were compared using Fisher's exact test. Continuous variables are presented as means and standard deviations. OS and RFS were estimated using the Kaplan-Meier method and compared using the log-rank test. Risk factors for OS and RFS were investigated using univariable Cox hazard model. A multivariable Cox hazard model was used to adjust for the risk factors. A complete case analysis was conducted. All statistical analyses were performed using R software (R Foundation for Statistical Computing, Vienna, Austria). All P-values were two-sided and those less than 0.05 were considered statistically significant. Results Patient characteristics A total of 320 patients with gastrointestinal cancer and comorbid CD underwent surgery during the study period. Of these, 216 had anorectal cancer, and 175 underwent APR or TPE. After the exclusion of two patients for whom no data were available on PILs, data for 173 patients (PIL: 135 patients and no PIL: 38 patients) were available for analysis (Fig. 1). Patient characteristics are shown in Table 1. Patients with PILs had more penetrating, proctos, or anal cancer; elevated carcinoembryonic antigen (CEA); advanced pT; open approach; and lateral pelvic node dissection, although they had less advanced pN. Additionally, patients with PILs underwent more R1/R2 resections and received more adjuvant chemotherapy. Flow diagram showing the patient selection process. APR, abdominoperineal resection; PILs, perianal inflammatory lesions; TPE, total pelvic exenteration Table 1.Patient Characteristics.FactorPerianal inflammatory lesionsYes (n=135)No (n=38)n%n%Age (years)<7012794.13592.1≥7053.725.3missing32.212.6SexFemale4634.11231.6Male8965.92668.4Duration of Crohn’s disease (months) *262.1112.3244.5130.7Ileum lesionNo2115.61026.3Yes11484.42873.7Colon lesionNo118.1821.1Yes12491.93078.9PenetratingNo6044.43592.1Yes7152.637.9missing43.000.0StricuringNo6245.91642.1Yes6951.12257.9missing43.000.0Tumor locationRectum4533.32360.5Proctos4432.6923.7Anus4634.1615.8Pathology findingswel2720.0821.1mod1410.9513.2por21.500.0sig96.725.3muc7051.92052.6Others21.555.6missing75.200.0CEA<57152.62873.7≥55540.7923.7missing75.212.6pTTis96.7410.5T132.237.9T22115.6718.4T34432.61642.1T4a118.137.9T4b3828.1513.2missing96.700.0APR: abdominoperineal resection, CEA: carcinoembryonic antigen, Lap: laparoscopic, LPN: lateral pelvic node, Rob: robotic, TPE: total pelvic exenteration*mean, standard deviation.FactorPerianal inflammatory lesionsYes (n=135)No (n=38)n%n%pN+3828.11539.508663.72360.5missing118.100.0pM+85.912.6011283.03797.4missing1511.100.0Neoadjuvant therapyNo11690.63386.8Yes129.437.9missing00.025.3ApproachLap/Rob1914.1718.4Open11484.43181.6missing21.500.0Surgical procedureAPR12290.43592.1TPE139.637.9Transanal approachNo10174.82565.8Yes3223.71334.2missing21.500.0LPN dissectionNo8865.23078.9Yes4029.6718.4missing75.212.6R010477.03489.511813.325.3264.400.0missing118.125.3Adjuvant chemotherapyNo6548.12463.2Yes6749.61334.2missing32.212.6 Patient Characteristics. Postoperative complications The incidence of overall complications was not significantly different between the patients with and without PILs (46.2% vs 45.9%, P=1.000). The details of the complications are shown in Table 2. Table 2.Postoperative Complications.Perianal inflammatory lesionsP-valueYes (n=135)No (n=38)n%n%Overall complications6146.21745.91.000Incisional surgical site infection1410.4615.80.393Intraabdominal pelvic abscess139.737.91.000Ileus/Intestinal obstruction64.525.31.000Wound dehiscence43.025.30.615Dysuria32.225.30.305Empty pelvic syndrome53.712.61.000High output syndrome21.500.01.000Urinary tract infection32.200.01.000 Postoperative Complications. OS and RFS The mean follow-up period for surviving patients was 54.4 months, with a standard deviation of 45.3. The OS was significantly higher in patients without PILs than in those with PILs (P=0.027); the 5-year OS was 73.3% (95% confidence interval (CI) 48.8-87.4%) and 46.8% (95%CI 36.4-56.6%), respectively (Fig. 2). Risk factors for OS are shown in Table 3. Female sex, undifferentiated pathology findings (por, sig, muc), elevated CEA, pT3, 4, pN+, M1, and R2 were significantly associated with poor OS. Neoadjuvant therapy and adjuvant chemotherapy did not improve OS. PILs were significantly associated poor OS after adjusting for the risk factors (hazard ratio [HR] 2.71, 95%CI 1.07-4.71, P=0.032). Overall survival and relapse-free survival. PILs: perianal inflammatory lesions Table 3.Risk Factors for Overall Survival and Relapse-free Survival.Risk factors for overall survivalUnivariable analysisMultivariable analysisHR95% CIP-valueHR95% CIP-valuePerianal inflammatory lesionsYes/No2.251.07-4.710.0322.711.06-6.920.037Age (years)0.980.96-1.010.144SexFemale/Male1.751.08-2.840.0241.850.98-3.460.057Duration of Crohn’s disease (months) *1.001.00-1.000.979PenetratingYes/No1.480.90-2.410.120StricuringYes/No0.950.58-1.550.845Tumor locationProctos/Rectum1.110.64-1.930.713Anus/Rectum0.840.46-1.560.588Pathology findingspor, sig, muc/wel, mod1.931.09-3.400.0242.021.00-4.090.051others/wel, mod0.000.00-Inf0.9960.000.00-Inf0.996CEA≥5/<53.161.89-5.30<0.0012.521.30-4.870.006pTTis-2/T3, 45.212.24-12.09<0.0011.490.54-4.110.440pNN+/N03.842.32-6.34<0.0014.272.12-8.60<0.001pMM1/M08.804.16-18.63<0.0011.690.56-5.100.352Neoadjuvant therapyYes/No2.131.08-4.190.029ApproachOpen/Lap, Rob3.490.85-14.330.082OperationTPE/APR1.920.91-4.030.086LPN dissectionYes/No1.560.95-2.560.079R1/01.830.89-3.740.0981.090.40-3.020.8632/08.113.35-19.670.00011.593.49-38.49<0.001Adjuvant chemotherapyYes/No1.981.20-3.290.008Risk factors for relapse-free survivalUnivariable analysisMultivariable analysisHR95% CIP-valueHR95% CIP-valuePerianal inflammatory lesionsYes/No1.730.96-3.120.0711.550.72-3.310.263Age (years)0.980.96-1.010.142SexFemale/Male1.851.20-2.860.0052.281.28-4.050.005Duration of Crohn’s disease (months) *1.001.00-1.000.353PenetratingYes/No1.631.05-2.510.0281.480.84-2.600.179StricuringYes/No1.030.66-1.600.898Tumor locationProctos/Rectum1.150.70-1.880.584Anus/Rectum0.850.49-1.460.548Pathology findingspor, sig, muc/wel, mod1.661.01-2.740.0451.230.64-2.350.539others/wel, muc0.000.00-Inf0.9960.000.00-Inf0.996CEA≥5/<52.261.46-3.52<0.0011.470.81-2.670.208pTT0-2/T3, 45.232.52-10.88<0.0012.571.03-6.420.043pNN+/N03.192.05-4.97<0.0012.981.66-5.36<0.001pMM1/M04.031.98-8.20<0.0010.660.22-1.920.441Neoadjuvant therapyYes/No2.011.06-3.800.032ApproachOpen/Lap, Rob2.220.90-5.500.084OperationTPE/APR1.230.59-2.560.577LPN dissectionYes/No1.440.92-2.240.108R1/01.911.00-3.640.0511.120.43-2.940.8132/07.913.23-19.39<0.00110.293.05-34.73<0.001Adjuvant chemotherapyYes/No2.111.35-3.310.001APR: abdominoperineal resection, CEA: carcinoembryonic antigen, CI: confidence interval, HR: hazard ratio, Lap: laparoscopic, LPN: lateral pelvic node, Rob: robotic, TPE: total pelvic exenteration*mean, standard deviation. Risk Factors for Overall Survival and Relapse-free Survival. APR: abdominoperineal resection, CEA: carcinoembryonic antigen, CI: confidence interval, HR: hazard ratio, Lap: laparoscopic, LPN: lateral pelvic node, Rob: robotic, TPE: total pelvic exenteration *mean, standard deviation. RFS was higher in patients without PILs than in those with PILs without statistical significance (P=0.065); the 5-year RFS was 52.5% (95% CI 30.8-70.3%) and 40.2% (95%CI 30.6-49.5%), respectively (Fig. 2). Risk factors for RFS are shown in Table 3. Female sex, intraabdominal intestinal perforation/fistula, undifferentiated pathology findings, elevated CEA, pT3, 4, pN+, M1, and R2 were significantly associated with poor OS. Neoadjuvant therapy and adjuvant chemotherapy did not improve RFS. It was unclear that PILs worsened RFS after adjusting for the risk factors (HR 1.54, 95%CI 0.72-3.31, P=0.263). Discussion This study investigated the impact of PILs in patients with CD and anorectal cancer, assuming that the increased surgical extent because of the presence of PILs increased postoperative complications, and the potential cancer risk associated with the presence of PILs worsened prognosis. In cases requiring surgery for anorectal cancer associated with CD, PILs were not associated with the occurrence of postoperative complications; however, they did influence cancer progression and prognosis. Various reports have been published on the risks and effects of carcinogenesis in patients with CD. Patients with CD have more than twice the risk of death from cancer and non-cancer diseases than those with other inflammatory bowel diseases[12]. Although CD patients have an increased overall cancer risk compared with that of the general population, no increase in rectal cancer incidence has been reported[13]. On the other hand, colitis is associated with an increased risk of colon cancer development in patients with CD[14]. A three-fold increased risk of anorectal cancer has been reported in CD patients with perianal lesions compared with the general population[15]. It has been suggested that various carcinogenic risks may exist in patients with CD, and the presence of PILs is a representative carcinogenic risk for rectal cancer[14,15]. In general, perianal abscesses and anal fistulas occur when bacteria invade the anal glands at the dentate line, causing an infection. As the anal gland infection worsens, an abscess forms under the skin around the anus, resulting in a perianal abscess. Furthermore, when the abscess passes into the skin, the pus is expelled, and any remaining traffic after pus expulsion becomes an anal fistula. Perianal abscesses and anal fistulas are a series of inflammatory lesions around anus[16]. In patients with Crohn's disease, in addition to the usual mechanisms of fistula formation, chronic inflammation and ulcers are also involved in the development of fistulas, often resulting in a more complex condition[17]. Because the presence of perianal lesions has important implications in the treatment of patients with CD, it is important to recommend an appropriately timed magnetic resonance imaging for accurate evaluation and appropriate treatment[18-20]. Adequate management of perianal lesions can prevent sepsis, reduce proctitis, and prevent extended surgery[21]. In this study, we investigated the impact of PILs on the short- and long-term outcomes of patients with CD and anorectal cancer. The presence of PILs was expected to increase the extent and duration of surgery in the short term, and there was concern about increased postoperative complications. However, the results of this study showed that the presence of PILs did not significantly increase postoperative complications. In the long term, there are concerns regarding potential residual cancer and postoperative cancer development because of residual PILs after APR or TPE. In addition, PILs may worsen the prognosis of CD, as these lesions may reflect advances in anorectal cancer. The results of this study showed that the OS was significantly worse in the presence of PILs. RFS was worse in the presence of PILs; however, this difference was not statistically significant. This suggests that, as we hypothesized, PILs worsen prognosis and that this reflects not only cancer recurrence, but also poor CD status. Therefore, in addition to R0 resection, the complete removal of PILs from which cancer may develop can contribute to an improved prognosis in patients with CD complicated by anorectal cancer. After surgery, more aggressive adjuvant chemotherapy to prevent cancer recurrence and more intensive treatment for CD to prevent the recurrence of PILs are also necessary. The strength of this study lies in the collection of data from leading Japanese facilities specializing in colorectal cancer treatment. Additionally, by collecting characteristic data on CD, the impact of CD complications on the prognosis of anorectal cancer can be examined. However, this study had some limitations. This study had a retrospective observational design, which implies that the potential influence of other factors on the association between PILs and prognosis may not have been completely eliminated. As we were unable to examine fistula-associated cancer, it is possible that the impact of the PIL on prognosis may be modified. This study included not only patients with colitic cancer but also a small number of patients with sporadic cancer, which may have influenced the results of the prognostic analysis. There is no information on the organs invaded by T4b cancer. We were unable to examine flap reconstruction after resection of anorectal cancer. This may have affected the results regarding postoperative complications. In addition, this was a long-term retrospective study; therefore, data on complications may not have been fully identified, and we were unable to control for the prognostic impact of advances in drugs and surgical treatment over time. There is a possibility that the group, including patients who received treatment more recently, might have better treatment outcomes. Since this study collected data from specialized treatment centers for inflammatory bowel disease in Japan, it may be difficult to directly apply the results of this study to treatments in general hospitals. In conclusion, in patients with CD and anorectal cancer, the presence of PILs did not increase the incidence of postoperative complications; however, it worsened prognosis. Author contributions NH designed the study, analyzed the data, and drafted the manuscript. YF, TT, and TN were responsible for acquisition of data. KH, KO, YF, TT, TN, KS, YA, and SI critically revised and supervised the manuscript for important intellectual content. All authors have approved the final draft of the manuscript. Ethics approval The protocol for this research project has been approved by the Ethics Committee of Kyoto University (Approval No. R2348) and this study was conducted in accordance with Declaration of Helsinki. Disclaimer Soichiro Ishihara is the Editor-in-Chief of Journal of the Anus, Rectum and Colon and on the journal's Editorial Board. He was not involved in the editorial evaluation or decision to accept this article for publication at all. Conflicts of Interest The authors declare that there are no conflicts of interest.